Skip to main content

Advertisement

Table 1 Baseline demographics and clinical characteristics of the subjects (safety population)

From: Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial

Variables Group 1 (n = 51) Group 2 (n = 55) Group 3 (n = 54) p
Age, years 74.8 ± 8.2 75.0 ± 9.6 75.8 ± 8.2 0.867
Female, % 60.8% 60.0% 63.0% 0.958
Education, %low/med/high 49/25.5/25.5 56.4/21.8/21.8 51.9/29.6/18.5 0.834
K-MMSE 12.9 ± 5.3 13.7 ± 4.3 14.4 ± 4.7 0.247
CDR 1.6 ± 0.6 1.7 ± 0.7 1.7 ± 0.5 0.877
GDS 4.9 ± 0.6 4.8 ± 0.7 4.9 ± 0.7 0.679
Body weight, kg 57.8 ± 8.7 59.2 ± 11.4 57.5 ± 9.9 0.628
BMI 23.9 ± 2.7 24.1 ± 3.6 23.6 ± 3.1 0.752
Duration of donepezil, years 1.8 ± 2.1 1.9 ± 2.0 2.0 ± 2.1 0.791
History of side effect d/t donepezil, % 3.9% 7.3% 3.7% 0.733
Hypertension, % 43.1% 58.2% 40.7% 0.147
DM, % 19.6% 27.3% 25.9% 0.661
Hyperlipidemia, % 33.3% 38.2% 35.2% 0.895
Brain injury, % 7.8% 7.3% 9.3% 0.937
Concomitant memantine 16/51, 31.4% 14/55, 25.5% 14/54, 25.9% 0.753
  1. Educational level up to 6 years (elementary school) was rated as low, up to 12 years (graduation high school) was rated as medium, and above 12 years was rated as high
  2. K-MMSE Korean version of Mini-Mental State Examination, CDR clinical dementia rating, GDS general deterioration scale, BMI body mass index, DM diabetes mellitus